Scarica l'app Stockscreener
9.775
5.68%
0.525
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché FGEN Giù?
Forum
Previsione
Precedente Chiudi:
$9.25
Aprire:
$9.38
Volume 24 ore:
45,389
Relative Volume:
0.93
Capitalizzazione di mercato:
$39.51M
Reddito:
$147.75M
Utile/perdita netta:
$-284.23M
Rapporto P/E:
-3.3362
EPS:
-2.93
Flusso di cassa netto:
$-317.54M
1 W Prestazione:
+37.58%
1M Prestazione:
+36.71%
6M Prestazione:
-24.92%
1 anno Prestazione:
+0.26%
Intervallo 1D:
$9.25
$9.85
Intervallo di 1 settimana:
$7.18
$10.10
Portata 52W:
$4.50
$21.94
Fibrogen Inc Stock (FGEN) Company Profile
Nome
Fibrogen Inc
Settore
Industria
Telefono
415-978-1200
Indirizzo
350 BAY STREET, SAN FRANCISCO, CA
Confronta FGEN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FGEN
Fibrogen Inc
|
9.775 | 33.83M | 147.75M | -284.23M | -317.54M | -2.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.12 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.50 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.02 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
645.90 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
303.40 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Fibrogen Inc Stock (FGEN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-08-08 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-06-26 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-06-26 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-06-26 | Downgrade | Stifel | Buy → Hold |
| 2023-06-26 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-06-02 | Aggiornamento | Stifel | Hold → Buy |
| 2023-01-31 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2023-01-26 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-09-22 | Downgrade | Goldman | Neutral → Sell |
| 2021-08-20 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2021-07-16 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-07-16 | Downgrade | Stifel | Buy → Hold |
| 2021-04-07 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2021-04-07 | Downgrade | Mizuho | Buy → Neutral |
| 2021-03-31 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-03-02 | Downgrade | Jefferies | Buy → Hold |
| 2021-02-01 | Iniziato | H.C. Wainwright | Buy |
| 2020-10-26 | Iniziato | Raymond James | Underperform |
| 2020-07-10 | Ripresa | Stifel | Buy |
| 2020-05-01 | Iniziato | Cowen | Market Perform |
| 2020-04-27 | Iniziato | BofA/Merrill | Neutral |
| 2019-05-29 | Ripresa | Goldman | Neutral |
| 2019-05-10 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2019-04-12 | Iniziato | Piper Jaffray | Neutral |
| 2019-02-11 | Ripresa | Stifel | Buy |
| 2018-12-19 | Aggiornamento | Citigroup | Neutral → Buy |
| 2017-08-08 | Reiterato | Leerink Partners | Outperform |
| 2017-08-08 | Reiterato | Stifel | Buy |
| 2017-07-21 | Downgrade | Goldman | Buy → Neutral |
| 2017-07-11 | Iniziato | Jefferies | Buy |
| 2016-02-11 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2016-01-21 | Iniziato | Credit Suisse | Neutral |
| 2015-12-04 | Iniziato | Citigroup | Buy |
| 2015-09-23 | Iniziato | Lake Street | Hold |
| 2015-07-29 | Iniziato | Citigroup | Buy |
| 2015-07-20 | Aggiornamento | Goldman | Neutral → Buy |
| 2014-12-09 | Iniziato | Stifel | Buy |
Mostra tutto
Fibrogen Inc Borsa (FGEN) Ultime notizie
FibroGen, Inc. (NASDAQ:FGEN) Q2 2025 Earnings Call Transcript - Insider Monkey
FibroGen’s Strategic Moves and Financial Outlook - The Globe and Mail
FibroGen raises China sale guidance to $210M, extends cash runway into 2028 as Phase II prostate cancer trial advances - MSN
FibroGen's Robust Finances and Promising Pipeline Earn Analyst's Buy Rating - AInvest
FibroGen Inc. Reports Q2 2025 Earnings: Strategic Moves, Cost Reductions, and Positive Clinical Updates - AInvest
FibroGen: Q2 Earnings Snapshot - New Haven Register
Fibrogen 2025 Q2 Earnings Record Net Income and Strong Revenue Growth - AInvest
Analysts Are Bullish on These Healthcare Stocks: FibroGen (FGEN), Revolution Medicines (RVMD) - The Globe and Mail
FibroGen Inc (FGEN) Q2 2025 Earnings Call Highlights: Strategic Moves and Cost Reductions ... - Yahoo Finance
FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
FibroGen Inc (FGEN) Q2 2025 Earnings Call Highlights: Strategic Moves and Cost Reductions ... By GuruFocus - Investing.com Canada
FibroGen's Strategic Pivot: China Exit and FG-3246's Oncology Promise Fuel Undervalued Biotech Opportunity - AInvest
FibroGen's 2025 Q2: Unraveling Key Contradictions in Roxadustat and FG-3246 Clinical Trial Strategies - AInvest
FibroGen's Q2 2025 Earnings Miss: A Catalyst for Long-Term Value or a Warning Signal? - AInvest
Transcript : FibroGen, Inc., Q2 2025 Earnings Call, Aug 11, 2025 - MarketScreener
FibroGen Q2 2025 slides: China sale extends runway amid clinical progress - Investing.com Canada
FibroGen (FGEN) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
FibroGen's Strategic Turnaround and Financial Resilience: A Path to Value Recovery? - AInvest
FibroGen Q2 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: FibroGen Q2 2025 revenue falls short, stock drops - Investing.com
FibroGen Inc earnings missed by $1.79, revenue fell short of estimates - Investing.com Nigeria
FibroGen's Financial Challenges and Catalyst-Driven Turnaround Potential - AInvest
FibroGen Secures $210M China Deal with AstraZeneca, Advances Cancer Drug Trials - Stock Titan
Fibrogen FGEN 2025Q2 Earnings Preview Upside Potential on Strong Revenue Growth - AInvest
FibroGen shares surge on FDA support for anemia drug in MDS patients - MSN
Is FibroGen Inc. affected by consumer sentimentRocket Return Picks - thegnnews.com
FibroGen Q2 Earnings: Analysts Predict Significant Decline, 2,770% Upside Potential - AInvest
Uncovering Potential: FibroGen's Earnings Preview - 富途牛牛
FibroGen Inc expected to post a loss of $2.31 a shareEarnings Preview - TradingView
FibroGen shares rise 11.75% intraday after positive FDA meeting for roxadustat Phase 3 trial. - AInvest
Fibrogen: HC Wainwright Raises PT to $43 from $10, Maintains Buy Rating - AInvest
FibroGen stock surges after FDA feedback on roxadustat for MDS anemia - Investing.com India
FibroGen advances roxadustat for anemia in myelodysplastic syndromes By Investing.com - Investing.com Australia
FibroGen advances roxadustat for anemia in myelodysplastic syndromes - Investing.com
FibroGen Announces Positive Type C Meeting with the FDA for - GlobeNewswire
FDA Green-Lights FibroGen's Novel Oral Treatment for MDS Anemia: 5x Better Than Placebo - Stock Titan
FibroGen, Inc. (NASDAQ:FGEN) Q4 2024 Earnings Call Transcript - MSN
FibroGen to Report Second Quarter 2025 Financial Results - The Manila Times
FibroGen Inc. Forms Bullish Flag — Upside AheadInvestment Plan With Growth Optimization Finalized - beatles.ru
How does FibroGen Inc. compare to its industry peersHigh-yield growth strategies - Jammu Links News
How volatile is FibroGen Inc. stock compared to the marketCapitalize on market trends with confidence - Jammu Links News
What is the dividend policy of FibroGen Inc. stockInvest confidently with professional guidance - Jammu Links News
Is FibroGen Inc. a good long term investmentRapidly growing investment returns - Jammu Links News
How does FibroGen Inc. generate profit in a changing economyGet exclusive access to premium stock research - Jammu Links News
What institutional investors are buying FibroGen Inc. stockCapitalize on momentum-driven stocks - Jammu Links News
What are analysts’ price targets for FibroGen Inc. in the next 12 monthsLightning-fast capital gains - Jammu Links News
Should I hold or sell FibroGen Inc. stock in 2025Get real-time updates on market trends - Jammu Links News
What are the latest earnings results for FibroGen Inc.Consistent triple-digit returns - Jammu Links News
What is the risk reward ratio of investing in FibroGen Inc. stockRealize exceptional returns through smart trading - Jammu Links News
How strong is FibroGen Inc. company’s balance sheetCapitalize on market shifts with expert advice - Jammu Links News
Press Release: FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update - 富途牛牛
Fibrogen Inc Azioni (FGEN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Fibrogen Inc Azioni (FGEN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Wettig Thane | CEO |
Mar 24 '25 |
Buy |
0.35 |
145,000 |
50,663 |
543,329 |
| Schoeneck James A | Director |
Mar 20 '25 |
Buy |
0.35 |
250,000 |
88,000 |
323,722 |
| Schoeneck James A | Director |
Mar 21 '25 |
Buy |
0.34 |
50,000 |
17,040 |
373,722 |
1.85%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):